Sourced of - Dr John Campbell - https://www.youtube.com/watch?v=K-kbeYdL1ng https://www.bmj.com/content/377/bmj.o1538 Proportion of budget derived from Industry European Medicines Agency, 89% (2022) Therapeutic Goods Administration, 96% US Food and Drug Administration, 56% (Total budget $6,100,000,000) Medicines and Healthcare Products Regulatory Agency, 86% Japan, PDMA 85% Health Canada, 50.5% (Total budget C$2,700,000,000) Australia TGA and Canada HC Conflicts of interests NOT available as public information Covid-19 vaccine committee members who declared a financial CoI UK, HMRA, 32% Australia, TGA, 50% Japan, PMDA, 75% Regulators do NOT routinely receive patient level datasets Australia, TGA Europe, EMA UK, MHRA Canada, HC Proportion of decisions to recommend new medicines v did not approve Australia, TGA, 94% Europe, EMA, 88% UK, MHRA, 98.5% US, FDA, 69% Canada, HC, 83% The revolving door FDA, nine out of 10 of its past commissioners, 2006 to 2019 went on to secure roles linked with pharmaceutical companies 1992, US Congress Passed the Prescription Drug User Fee Act (PDUFA) Allowing industry to pay “user fees” directly to FDA 2005 UK, House of Commons’ health committee Evaluated the influence of the drug industry on health policy, including the Medicines and Healthcare Products Regulatory Agency (MHRA). The committee was concerned